Jama Pitman - Deciphera Pharmaceuticals Quality Regulatory
| DCPHDelisted Stock | USD 13.32 0.36 2.63% |
Insider
Jama Pitman is Quality Regulatory of Deciphera Pharmaceuticals LLC
| Age | 44 |
| Phone | 781 209 6400 |
| Web | https://www.deciphera.com |
Jama Pitman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jama Pitman against Deciphera Pharmaceuticals stock is an integral part of due diligence when investing in Deciphera Pharmaceuticals. Jama Pitman insider activity provides valuable insight into whether Deciphera Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Deciphera Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Deciphera Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jama Pitman over six months ago Acquisition by Jama Pitman of 5576 shares of Deciphera Pharmaceuticals subject to Rule 16b-3 |
Deciphera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2662) % which means that it has lost $0.2662 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5037) %, meaning that it created substantial loss on money invested by shareholders. Deciphera Pharmaceuticals' management efficiency ratios could be used to measure how well Deciphera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Deciphera Pharmaceuticals LLC currently holds 25.88 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Deciphera Pharmaceuticals has a current ratio of 5.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Deciphera Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jeffrey Zerillo | Prestige Brand Holdings | 63 | |
| Kevin Anderson | Supernus Pharmaceuticals | 62 | |
| Frank Mottola | Supernus Pharmaceuticals | 51 | |
| Adel Mekhail | Prestige Brand Holdings | 63 | |
| Steven Sullivan | Avadel Pharmaceuticals PLC | 59 | |
| Craig Johnstone | Evotec SE ADR | 54 | |
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| Jean Filippi | Phibro Animal Health | N/A | |
| Jason Rickard | Ironwood Pharmaceuticals | 53 | |
| Beth Calitri | Ironwood Pharmaceuticals | N/A | |
| Matthias Evers | Evotec SE ADR | 51 | |
| Jacob MBA | Amphastar P | 50 | |
| Thomas Harvey | Alkermes Plc | N/A | |
| Floyd MD | Alkermes Plc | 87 | |
| Anja Bosler | Evotec SE ADR | N/A | |
| MBA MBA | Evotec SE ADR | 54 | |
| Christian Dargel | Evotec SE ADR | 53 | |
| Jonathan Rubin | Supernus Pharmaceuticals | 63 | |
| Damian Finio | Phibro Animal Health | 54 | |
| Dean Siegal | Prestige Brand Holdings | N/A | |
| Christian PharmD | Avadel Pharmaceuticals PLC | N/A | |
Management Performance
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 |
Deciphera Pharmaceuticals Leadership Team
Elected by the shareholders, the Deciphera Pharmaceuticals' board of directors comprises two types of representatives: Deciphera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Deciphera. The board's role is to monitor Deciphera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Deciphera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Deciphera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Flynn, Founder, Chief Scientific Officer | ||
| Daniel Martin, Chief Commercial Officer | ||
| Margarida Duarte, Senior International | ||
| Stephen Ruddy, VP Officer | ||
| Kevin Brodbeck, Senior Officer | ||
| Lisa Price, Senior Officer | ||
| Matthew MD, Executive Officer | ||
| Jeffrey JD, Senior Counsel | ||
| Steven Hoerter, President CEO | ||
| Dashyant Dhanak, Executive Officer | ||
| Thomas JD, CFO VP | ||
| Jennifer Larson, Senior Relations | ||
| Jama Pitman, Quality Regulatory |
Deciphera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Deciphera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Shares Owned By Insiders | 28.48 % | |||
| Shares Owned By Institutions | 72.03 % | |||
| Number Of Shares Shorted | 3.92 M | |||
| Price To Earning | (6.78) X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |